I-BASE HIV TREATMENT BULLETINImportant note: Information in this article was accurate in August 2007. The state of the art may have changed since the publication date.
Click here to return to I-BASE main menu
DonateNow

Does diabetes have the same impact on cardiovascular risk in HIV-infected patients as it does in the general population?

HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007

Michael Dube, for NATAP.org


The multicentre, multi-continent DAD study has contributed greatly to our increased understanding of risk factors for development of cardiovascular disease in HIV-infected individuals. Signe Worm from Copenhagen presented an analysis of just how much does a diagnosis of diabetes contribute to the risk of myocardial infarction.

Current NCEP guidelines consider a diagnosis of diabetes to be a “coronary heart disease (CHD) risk equivalent”, meaning that if you have diabetes you should be considered to be at the same risk for heart attack as someone already diagnosed with CHD, and thus lipid problems should be managed just as aggressively in diabetics.

Older data from the general population to justify this approach, but some more recent studies have not confirmed that the magnitude of risk from diabetes alone is as great - thus this question of diabetes being a CHD risk equivalent is somewhat controversial in the general population as well.

Published guidelines for managing lipid disorders in HIV-positive patients on ART have stated that the NCEP guidelines should be followed just as they are in the general population. However, it has not been documented in HIV-positive patients, that a diagnosis of diabetes carries the same CHD risk as it does in the general population. It is possible, because insulin resistance/impaired glucose tolerance may be present for decades before a diagnosis of diabetes is made in the general population, that there is cumulative risk incurred over a prolonged period even before overt diabetes is diagnosed.

With HIV infection, if insulin resistance/impaired glucose tolerance is caused by antiretroviral therapy and is present only for a much shorter period of time before over diabetes is diagnosed, or if diagnosis of diabetes is made much sooner because of increased health care visits and routine blood glucose monitoring, or is diagnosed at a much younger age, a current diagnosis of diabetes may have a much lesser impact on CHD risk.

The DAD data confirm that diabetes increases CHD risk, but a diagnosis of diabetes mellitus without known pre-existing CHD provided only about one third of the CHD event risk that a prior CHD diagnosis gave. This would suggest that perhaps, a diabetes diagnosis in an HIV-infected individual should not necessarily lead to lipid management that is as aggressive as in an HIV-infected individual with pre-existing CHD but no diabetes.

Alternatively, it could be argued that because HIV infection itself increases CHD risk, and because diabetes is discovered sooner, this early diabetes diagnosis would provide an excellent opportunity for preventative early lipid intervention in HIV- infected diabetics well before there is longer-term vascular damage from years of insulin resistance and impaired glucose tolerance. Importantly, the DAD results do not address the central question of, will the risks from following current NCEPguidelines for diabetics outweigh the benefits in those with HIV?

For now, it seems reasonable to continue to follow the NCEP guidelines until there are more data including external validation of the DAD results on other prospective cohorts.

Ref: Worm S et al. Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals?

2007-08-10
IB070808-25


©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.